NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-600 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems. The minimum award is $50,000. There is no maximum price requirement; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass and nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
Funding Opportunity PAR-18-604 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support enhanced human and animal food safety by strengthening the capacity, collaboration, and integration of food-safety laboratories and networks, thereby facilitating an effective and coordinated response to future human and animal food safety issues. The current FOA solicits applications from FDA's Veterinary Laboratory Investigation and Response Network laboratories for research related to emerging public food safety issues identified by the Vet-LIRN network office (VPO), for equipment and personnel necessary to expand laboratory capability and capacity, and for other related activities. This cooperative agreement program is intended to build domestic laboratory capacity as put forth in the Food Safety Modernization Act (FSMA), by developing the Vet-LIRN laboratory Network capabilities and capacity to investigate potential animal foodborne illness outbreaks.
Funding Opportunity PAR-18-596 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease. Further information on the specific topics of interest will be announced through a series of notices published in late January and early February of 2018.
Funding Opportunity PAR-18-597 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or observational study. Research data from observational cohort studies can enhance clinical study design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential research participants, and outcomes that are important to patients. CO studies also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in future clinical studies. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.
Funding Opportunity PA-18-602 from the NIH Guide for Grants and Contracts. The purpose of this FOA is two-fold: (1) to advance identification of male-females differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research
Funding Opportunity PA-18-601 from the NIH Guide for Grants and Contracts. The purpose of this FOA is two-fold: (1) to advance identification of male-females differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research
Funding Opportunity PA-18-603 from the NIH Guide for Grants and Contracts. The purpose of this FOA is two-fold: (1) to advance identification of male-females differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research
Notice NOT-HD-17-033 from the NIH Guide for Grants and Contracts
Notice NOT-GM-18-016 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-599 from the NIH Guide for Grants and Contracts. The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000, after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000.
Funding Opportunity PA-18-590 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify grantee organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of grantee organization may be submitted in response to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of grantee organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of grantee organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.
Funding Opportunity PA-18-589 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify grantee organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of grantee organization status, often referred to in this announcement as Successor-In-Interest, may be submitted in response to this FOA. Applications for change of grantee organization status are considered prior approval requests (as described in Section 8.1.2.8 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although successor-in-interest requests may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.
Funding Opportunity PAR-18-587 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) research and development of assistive technology for individuals with Alzheimer's disease and related dementias (ADRD) and their caregivers/care partners, to enhance their health and well-being, reduce illness and disability, and improve quality of life. Particularly of interest are technologies for providing psychosocial support (enhancing mood, mitigating the effects of loneliness, and enhancing social connection and communication), reducing stress (e.g., through the provision of biofeedback or other forms of behavioral therapy) and assisting with care management and activities of daily living. To achieve these ends, this FOA encourages a multi-disciplinary approach to foster collaborations between geriatricians (particularly those with knowledge of cognitive impairment and dementia), psychologists, neurologists, computer scientists, and mechanical, electrical and software engineering professionals. Applications should demonstrate the potential for broad population impact, including that the proposed assistive technology is: 1. Innovative 2. Efficacious and effective 3. Scalable 4. Low-cost
Funding Opportunity PAR-18-588 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) research and development of assistive technology for individuals with Alzheimer's disease and related dementias (ADRD) and their caregivers/care partners, to enhance their health and well-being, reduce illness and disability, and improve quality of life. Particularly of interest are technologies for providing psychosocial support (enhancing mood, mitigating the effects of loneliness, and enhancing social connection and communication), reducing stress (e.g., through the provision of biofeedback or other forms of behavioral therapy) and assisting with care management and activities of daily living. To achieve these ends, this FOA encourages a multi-disciplinary approach to foster collaborations between geriatricians (particularly those with knowledge of cognitive impairment and dementia), psychologists, neurologists, computer scientists, and mechanical, electrical and software engineering professionals. Applications should demonstrate the potential for broad population impact, including that the proposed assistive technology is: 1. Innovative 2. Efficacious and effective 3. Scalable 4. Low-cost
Funding Opportunity PAR-18-595 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies.
Funding Opportunity PAR-18-594 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a R34. The NIAMS expects such trials to be hypothesis driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS.
Funding Opportunity PA-18-586 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.
Funding Opportunity RFA-AG-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.
Funding Opportunity RFA-RM-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Research Opportunity Announcement (ROA) is to establish the HuBMAP Integration, Visualization and Engagement (HIVE) Collaboratory that will 1) manage the data generated by the Consortium, 2) coordinate internal and external Consortium activities, 3) develop novel tools for visualizing, searching and modelling data and 4) build an atlas of tissue maps. The HIVE will be composed of four Components all of which are expected to work closely together to act as the unified backbone for HuBMAP. The HIVE is expected to work closely with the other funded projects as part of the HuBMAP Consortium to catalyze development of a framework for mapping the human body with high spatial resolution. An application may propose only one Component. However, a coordinated set of separate applications, each describing a separate Component but with a common vision, can be proposed.
Notice NOT-OD-18-129 from the NIH Guide for Grants and Contracts